Research In Brief
Knee arthroplasty is worth it: Total knee replacement surgery is generally cost-effective, according to a study in the June 22 issue of the Archives of Internal Medicine. The authors, from several Boston hospitals, Boston University, Harvard, Yale and the University of California, calculated the cost per quality-adjusted life-year from knee replacement to be $18,300 compared to non-surgical management; in a predefined high-risk group the ratio increased to $28,100, but both numbers fall below typical cost-effectiveness thresholds, the researchers say. Costs were comparatively higher at low-volume facilities, the paper pointed out. The data was derived from a computer simulation model populated with cost and outcomes data on knee osteoarthritis patients from Medicare claims and other sources. An accompanying editorial in the journal touts the results as important, but also says the study illustrates the challenges of technology assessments and comparative effectiveness research. The cost-effectiveness ratio is very sensitive to the outcomes denominator, but because there are no gold standard randomized trials comparing knee replacement and medical management, the precise accuracy of the data is in question, the editorial points out
Keep up with the top medtech business and regulatory news.
More from Archive
A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.
REUSE OF DISPOSABLE CARDIAC CATHETERS TARGETED BY FDA in an effort to address safety concerns about reuse of single-use products. The cardiac catheter product area "seems to jump up as one that is an area for us to focus on," Larry Spears, director of the Office of Compliance's Division of Enforcement III in FDA's Center for Devices and Radiological Health, said June 24 at a Food Drug and Law Institute conference held in Washington, D.C.
St Jude Medical and Spire are to develop anti-bacterial heart valve sewing cuffs using Spire's Spi-Argent silver coating process. The agreement covers a variety of valve designs as well as ancillary components. The treatment is aimed at reducing the incidence of endocarditis, a rare but dangerous complication of valve transplant which has a mortality rate as high as 60%.
Nissho saw sales rise only 1% to ¥17 billion ($930 million) in the year to March 1997. The Japanese company's net income was Yen3 billion, compared with Yen1.7 billion for the previous year, reports Reuters. Nissho produces disposable medical equipment.
More from Medtech Insight
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
Class III devices and panel-track supplements approved by US FDA’s Center for Devices and Radiological Health. Data derived from FDA.gov. Updated weekly.
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.